Ester Sklarsky joins Sound Bioventures

Read about Ester Sklarsky and how her curiosity for life-science and innovation shaped a career in VC, permitting her to pursue the therapeutics of tomorrow and make a difference for patients.

Today we welcome Ester Sklarsky to the Sound Bioventures investment team as an Associate. Ester will manage our dealflow, identify new investment opportunities and conduct scientific and commercial due diligence.

Ester joins us from Industrifonden where she made life science venture capital investments as an analyst as well as an associate. Ester also has prior experience as a management consultant at Sirona Health Solutions, where she worked with key stakeholders in the Swedish public healthcare sector, as well as as an equity analyst at the bank DNB, where she focused on the Biotech sector.

Ester holds a bachelor’s degree in Biomedicine from the Karolinska Institute and a master’s degree in Bioentrepreneurship, also fromthe  Karolinska Institute.

Ester will be based at the Stockholm, SE, office.

ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

-ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline to enter the clinic – -First patient expected to be enrolled in Q2 2024- Valencia, Spain, February 28th, 2024 – ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the m ...

Subscribe

* indicates required